Analytical Data
-
Gene name
MAGEB18
- Application
-
Alternative Names
B430216B18Rik; MAGBI_HUMAN; MAGE-B18 antigen; MAGEB18; MAGEB18 antigen; Melanoma antigen family B; 18; Melanoma-associated antigen B18; MGC114496; RGD1560369; RP23-289C5.3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96M61
-
Expression Region
1-343aa
-
AA Sequence
MPRGQKSKLR AREKRHQARC ENQDLGATQA TVAEGESPSP AYLLFGDRPQ NLPAAETPSI PEALQGAPST TNAIAPVSCS SNEGASSQDE KSLGSSREAE GWKEDPLNKK VVSLVHFLLQ KYETKEPITK GDMIKFVIRK DKCHFNEILK RASEHMELAL GVDLKEVDPI RHYYAFFSKL DLTYDETTSD EEKIPKTGLL MIALGVIFLN GNRAPEEAVW EIMNMMGVYA DRKHFLYGDP RKVMTKDLVQ LKYLEYQQVP NSDPPRYEFL WGPRAHAETS KMKVLEFVAK IHDTVPSAFP SCYEEALRDE EQRTQARAAA RAHTAAMANA RSRTTSSSFS HAK
-
Molecular Weight
38.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEB18, a member of the melanoma-associated antigen gene family, has garnered attention in cancer immunology due to its potential role as a tumor-associated antigen. Expressed predominantly in testicular germ cells and various types of cancers, including melanoma, MAGEB18 is not typically found in normal somatic tissues, making it a promising target for cancer immunotherapy. Researchers are particularly interested in its expression patterns and mechanisms, as MAGEB18 may elicit an immune response capable of targeting tumor cells while sparing healthy tissues. Recent advancements in recombinant protein technology have facilitated the production of MAGEB18, allowing for detailed studies on its structure and function. Understanding how MAGEB18 interacts with immune cells and contributes to cancer progression could lead to the development of novel therapeutic strategies, including cancer vaccines and targeted immune therapies, aimed at bolstering the body’s natural defenses against tumors. The ongoing research into MAGEB18 not only highlights its potential clinical applications but also underscores the importance of identifying and characterizing tumor-associated antigens in the quest for more effective cancer treatments.
